首页> 外国专利> Treatment and prevention of elevated lyso-PAF levels mediated mental illnesses with PAF antagonists

Treatment and prevention of elevated lyso-PAF levels mediated mental illnesses with PAF antagonists

机译:用PAF拮抗剂治疗和预防溶血PAF介导的精神疾病升高

摘要

The invention refers to the treatment of lyso-paf-mediated diseases with paf antagonists and a procedure for determining their efficacy. According to the invention for treating a disease caused by lyso paf ( 1-0-alkyl-sn-glyceryl-3-phosphocholine) as the precursor and metabolit of paf is found in elevated amounts in the liquor of mental and/or inflammatory diseases. Lyso paf regulates via its own receptor the paf receptors on human neutrophils which are then inhibited by paf antagonists. According to the invention for treating a mental and/or inflammatory diseases caused by lyso paf an effective amount of at least one paf antagonist is administered to a subject requiring said treatment, wherein the paf antagonist is a hydrophilic or non-hydrophilic triazolothieno-diazepine or a homologue thereof, a ginkgolide, a ginkgolide mixture or a synthetic ginkgolide derivate, or an analogue of the paf or a mixture with/of these compounds. IMAGE
机译:本发明涉及用paf拮抗剂治疗溶血-paf介导的疾病和确定其功效的方法。根据本发明,用于治疗由溶血paf(1-0-烷基-sn-甘油基-3-磷酸胆碱)引起的疾病的方法在精神疾病和/或炎性疾病的溶液中以增加的量存在于paf中。溶血paf通过其自身的受体调节人类嗜中性粒细胞上的paf受体,然后被paf拮抗剂抑制。根据用于治疗由溶血paf引起的精神和/或炎性疾病的本发明,将有效量的至少一种paf拮抗剂施用给需要所述治疗的受试者,其中所述paf拮抗剂是亲水性或非亲水性的三唑并菲二氮杂卓或其同系物,银杏内酯,银杏内酯混合物或合成银杏内酯衍生物,或paf的类似物或与这些化合物的混合物。 <图像>

著录项

  • 公开/公告号DE69133083T2

    专利类型

  • 公开/公告日2003-05-08

    原文格式PDF

  • 申请/专利权人 KORTH RUTH-MARIA;

    申请/专利号DE1991633083T

  • 发明设计人 KORTH RUTH-MARIA;

    申请日1991-11-04

  • 分类号A61K31/365;A61K31/685;A61K31/4196;A61P25/18;A61K31/5517;

  • 国家 DE

  • 入库时间 2022-08-21 23:39:56

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号